IMPDH Antibody (D-3): sc-365171

IMPDH Antibody (D-3) is a mouse monoclonal IgG1 antibody that detects inosine-5′-monophosphate dehydrogenase 1 (IMPDH1) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). IMPDH1, a member of the guanosine monophosphate reductase (GMPR) family, plays a crucial role in regulating cell growth by catalyzing the rate-limiting step in the de novo synthesis of guanine nucleotides, which are essential for DNA and RNA synthesis. IMPDH1 is predominantly expressed in normal leukocytes, while IMPDH2 is more prevalent in various tumors, highlighting IMPDH1′s significance in both normal physiology and cancer biology. IMPDH1 forms a homotetramer that is widely distributed in photoreceptors, where IMPDH1 is involved in cyclic nucleoside metabolism, a process vital for maintaining cellular function and signaling. Mutations in IMPDH1 have been linked to autosomal dominant retinitis pigmentosa type 10 (RP10) and the development of malignant tumors, with studies indicating that protein misfolding and aggregation, rather than reduced enzymatic activity, contribute to the severe phenotypes observed in these conditions. IMPDH1 presents a promising therapeutic target, particularly through strategies that involve simultaneous suppression of IMPDH1 transcripts while supplementing guanosine triphosphate (GTP) in retinal tissues, potentially offering new avenues for treatment in related disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IMPDH Antibody (D-3) References:

1. Covalent inactivation of Mycobacterium thermoresistibile inosine-5'-monophosphate dehydrogenase (IMPDH).  |  Trapero, A., et al. 2020. Bioorg Med Chem Lett. 30: 126792. PMID: 31757668
2. IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex.  |  Valvezan, AJ., et al. 2020. JCI Insight. 5: PMID: 32271165
3. IMPDH-Based Cytoophidium Structures as Potential Theranostics in Cancer.  |  Keppeke, GD., et al. 2020. Mol Ther. 28: 1557-1558. PMID: 32534605
4. CTPS and IMPDH form cytoophidia in developmental thymocytes.  |  Peng, M., et al. 2021. Exp Cell Res. 405: 112662. PMID: 34022203
5. Meta-analysis of the associations of IMPDH and UGT1A9 polymorphisms with rejection in kidney transplant recipients taking mycophenolic acid.  |  Cheng, L., et al. 2022. Eur J Clin Pharmacol. 78: 1227-1238. PMID: 35524809
6. The IMPDH cytoophidium couples metabolism and fetal development in mice.  |  Peng, M., et al. 2024. Cell Mol Life Sci. 81: 210. PMID: 38717553
7. Thiophenyl Derivatives of Nicotinamide Are Metabolized by the NAD Salvage Pathway into Unnatural NAD Derivatives That Inhibit IMPDH and Are Toxic to Peripheral Nerve Cancers.  |  Theodoropoulos, PC., et al. 2024. ACS Chem Biol. 19: 1339-1350. PMID: 38829020
8. IMPDH inhibitors upregulate PD-L1 in cancer cells without impairing immune checkpoint inhibitor efficacy.  |  Zheng, MM., et al. 2024. Acta Pharmacol Sin.. PMID: 39592732
9. Induction of IMPDH-Based Cytoophidia by a Probable IMP-Dependent ARL13B-IMPDH Interaction.  |  Alijani, N. and Yazdanparast, R. 2024. Biochemistry (Mosc). 89: 2287-2291. PMID: 39865040
10. The influence of IMPDH activity on ciliogenesis and adipogenesis of 3T3-L1 cells while undergoing differentiation.  |  Shahdadnejad, K. and Yazdanparast, R. 2025. Biochim Biophys Acta Mol Cell Biol Lipids. 1870: 159603. PMID: 39961477

The preferred IMPDH antibody is IMPDH Antibody (F-6): sc-166551.